Published online 30 May 2014 Nucleic Acids Research, 2014, Vol. 42, No. 12 7489–7527 doi: 10.1093/nar/gku447
SURVEY AND SUMMARY Type II restriction endonucleases––a historical perspective and more Alfred Pingoud1,*,†, Geoffrey G. Wilson2,† and Wolfgang Wende1
1Institute of Biochemistry, Justus-Liebig-University Giessen, Heinrich-Buff-Ring 58, D-35392 Giessen, Germany and 2New England Biolabs Inc., 240 County Road, Ipswich, MA 01938-2723, USA Downloaded from
Received January 7, 2014; Revised May 02, 2014; Accepted May 7, 2014
ABSTRACT combat viral infections, these enzymes allow unmanageable http://nar.oxfordjournals.org/ tangles of macromolecular DNA to be transformed with This article continues the series of Surveys and Sum- unsurpassable accuracy into convenient, gene-sized pieces, maries on restriction endonucleases (REases) begun a necessary first step for characterizing genomes, sequenc- this year in Nucleic Acids Research.Herewedis- ing genes, and assembling DNA into novel genetic arrange- cuss ‘Type II’ REases, the kind used for DNA anal- ments. It seems unlikely that today’s Biomedical Sciences ysis and cloning. We focus on their biochemistry: and the Biotechnology industry would have developed with- what they are, what they do, and how they do it. Type out Type II restriction enzymes, and certainly not at the
II REases are produced by prokaryotes to combat startling pace we have witnessed since their discovery only at Bibliothekssystem der Universitaet Giessen on February 10, 2015 bacteriophages. With extreme accuracy, each recog- a few decades ago. nizes a particular sequence in double-stranded DNA and cleaves at a fixed position within or nearby. The INTRODUCTION discoveries of these enzymes in the 1970s, and of the uses to which they could be put, have since im- Several reviews of restriction endonucleases (REases) have pacted every corner of the life sciences. They be- appeared as Surveys and Summaries in Nucleic Acids Re- came the enabling tools of molecular biology, ge- search recently. These concerned the somewhat esoteric Type I (1), Type III (2) and Type IV (3) REases; highlights netics and biotechnology, and made analysis at the of half a century of REase research and discovery (4); and most fundamental levels routine. Hundreds of dif- the connection between REases and genetic addiction sys- ferent REases have been discovered and are avail- tems (5). The present review focuses on the more familiar, able commercially. Their genes have been cloned, Type II REases, the ‘work horses’ (6) of modern molec- sequenced and overexpressed. Most have been char- ular biology, used daily in laboratories for DNA analysis acterized to some extent, but few have been studied and gene cloning. This review is partly historical, as were in depth. Here, we describe the original discoveries the others, and emphasizes the importance of the enzymes in this field, and the properties of the first Type II EcoRI and EcoRV, among the first REases discovered, REases investigated. We discuss the mechanisms and the two most thoroughly studied (Figure 1). It is also of sequence recognition and catalysis, and the var- partly contemporary, and provides an up-to-date overview ied oligomeric modes in which Type II REases act. of the field, although one that is necessarily not compre- hensive. Over 350 different Type II prototype REases are We describe the surprising heterogeneity revealed known, each unique in its biochemistry, and with its own by comparisons of their sequences and structures. story to tell. For most of these, anywhere from a few to over one hundred similar enzymes from sequenced organ- isms are known, some characterized but most putative. And PROLOGUE REBASE (rebase.neb.com/rebase/rebase.html), the defini- We wonder what Molecular Biology would look like today tive source for information on REases and their compan- had Type II restriction enzymes not been discovered. Syn- ion proteins (7), lists over 8000 research publications in this thesized in bewildering variety by bacteria and archaea to field, too many by far to be discussed here. We apologize in
*To whom correspondence should be addressed. Tel: +49 641 35401; Fax: +49 641 35409; Email: [email protected] †The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.